NEW YORK, NY / ACCESS Newswire / March 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Biohaven’s pipeline drug BHV-7000 has failed to meet the primary endpoint in a pivotal Phase II/III bipolar trial, sinking ...

Biohaven in recent months has reported a clinical stumble in spinal muscular atrophy, alongside a Phase I readout for its ...

Highlights,Institutional investments in Biohaven Ltd. have shown recent increases.,The company focuses on developing ...

Biohaven stock tumbled for the second day running Tuesday after its bipolar mania treatment failed in a three-week study.Analysts called the stock reaction overdone, while Chief Executive Vlad Coric ...

Biohaven’s bipolar disorder candidate has failed to improve mania symptoms in a phase 2/3 trial. | Biohaven’s bipolar disorder candidate has failed to improve mania symptoms in a phase 2/3 trial.

Biohaven has a 1 year low of $26.80 and a 1 year high of $60.46. The stock’s 50-day simple moving average is $37.06 and its 200-day simple moving average is $42.08.

Robert Lenz is leaving the brain drug developer to “pursue other interests.” Elsewhere, Atara is cutting half of its staff ...

Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range ...

Biohaven Ltd. (NYSE:BHVN – Get Free Report) fell 6.1% during mid-day trading on Monday after the company announced weaker ...

Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of total IgG, differentiating Biohaven's new small-molecule class of degraders from the monoclonal ...